dict.md logo
Choose languages of interest
SELECT >>
English
Advertisement:
Translation
 
0 translations
 
Definition
 
enEnglish
sodium stibogluconate definition: Pentavalent antimony (Sb) in differential complex formation with gluconic acid with established leishmanicidal use and potential antitumor activity. The Sb moiety of sodium stibogluconate (SSG) may inhibit protein tyrosine phophorylases (PTPases) by covalently modifying sulfhydryl groups in PTPase cysteine residues, resulting in specific inactivation of SH2 domain-containing tyrosine phosphatases-1 and -2 (SHP-1 and SHP-2), PTPases which negatively regulate interferon (IFN) signaling; enhancement of IFN-induced Stat1 tyrosine phosphorylation; and induction of cellular protein tyrosine phosphorylation. SSG in combination with IFN-alpha may synergize to overcome tumor cell resistance to IFN-alpha-mediated apoptosis. Check for "http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=475763&idtype=1" active clinical trials or "http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=475763&idtype=1&closed=1" closed clinical trials using this agent. ("http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C61083" NCI Thesaurus)
Sodium Stibogluconate definition: Pentavalent antimony (Sb) in differential complex formation with gluconic acid with leishmanicidal and potential antineoplastic activities. The Sb moiety of sodium stibogluconate (SSG) may inhibit protein tyrosine phosphorylases (PTPases) by covalently modifying sulfhydryl groups in PTPase cysteine residues, resulting in specific inactivation of SH2 domain-containing tyrosine phosphatases-1 and -2 (SHP-1 and SHP-2), PTPases which negatively regulate interferon (IFN) signaling; enhancement of IFN-induced Stat1 tyrosine phosphorylation; and induction of cellular protein tyrosine phosphorylation. SSG in combination with IFN-alpha may synergize to overcome tumor cell resistance to IFN-alpha-mediated apoptosis.
 
Examples
 

We calculated the cost-effectiveness of intralesional and intramuscular administration of the pentavalent antimonial drug sodium stibogluconate, HNTPO's current CL 'standard treatment'.

Richard Reithinger et al.

BMC Infectious Diseases 7 (7), 30 Jan 2007

Patients attending HNTPO leishmaniasis treatment centers were treated with the pentavalent antimonial drug sodium stibogluconate (SSG), either given intralesionally (up to five 2 – 5 ml injections given every 5 – 7 days) or intramuscularly (20 mg/kg bodyweight for 21 consecutive days).

Richard Reithinger et al.

BMC Infectious Diseases 7 (7), 30 Jan 2007

Item Total Cost (US$) Non-Medical Costs Expatriate Staff 38,880.00 National Staff 39,780.00 Transport 10,800.00 Tools and Equipment 7,740.00 Communication 3,120.00 Operational 28,500.00 Sub-total 128,820.00 Medical Costs Patient record forms [@US$0.1 pp] 1,639.00 Laboratory materials for drug administration [@US$ 0.5 pp visit] 63,265.40 Sodium stibogluconate [@US$ 3 per vial; 12,440 vials used] 37,320.03 Sub-Total 102,224.43 7% Administrative Overhead Cost 16,173.11 Total Program Cost 247,217.54 Listed are costs for all human and operational resources directly involved in leishmaniasis treatment activities as implemented in Kabul by HealthNet TPO (HNTPO).

Richard Reithinger et al.

BMC Infectious Diseases 7 (7), 30 Jan 2007

The cost of the sodium stibogluconate is based on patient treatment regimens outlined in Materials and Methods.

Richard Reithinger et al.

BMC Infectious Diseases 7 (7), 30 Jan 2007

Drug efficacy estimates came from studies evaluating the therapeutic efficacy of pentavalent antimonial drugs (SbV) for cutaneous leishmaniasis, i.e. sodium stibogluconate (†) or meglumine antimoniate (‡)

Richard Reithinger et al.

BMC Infectious Diseases 7 (7), 30 Jan 2007

 
Publications
 
0 publications